Related Experiment Video
Updated: May 18, 2026
Unraveling Entropic Rate Acceleration Induced by Solvent Dynamics in Membrane Enzymes
Published on: January 16, 2016
Molecular dynamics analysis of a series of 22 potential farnesyltransferase substrates containing a CaaX-motif
Sérgio F Sousa1, João T S Coimbra, Diogo Paramos
1REQUIMTE, Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade do Porto, Rua do Campo Alegre, s/n, 4169-007, Porto, Portugal. sergio.sousa@fc.up.pt
Abstract:
Protein farnesyltransferase (FTase) is an important target in many research fields, more markedly so in cancer investigation since several proteins known to be involved in human cancer development are thought to serve as substrates for FTase and to require farnesylation for proper biological activity. Several FTase inhibitors (FTIs) have advanced into clinical testing. Nevertheless, despite the progress in the field several functional and mechanistic doubts on the FTase catalytic activity have persisted. This work provides some crucial information on this important enzyme by describing the application of molecular dynamics simulations using specifically designed molecular mechanical parameters for a variety of 22 CaaX peptides known to work as natural substrates or inhibitors for this enzyme. The study involves a comparative analysis of several important molecular aspects, at the mechanistic level, of the behavior of substrates and inhibitors at the dynamic level, including the behavior of the enzyme and peptides, as well as their interaction, together with the effect of the solvent. Properties evaluated include the radial distribution function of the water molecules around the catalytically important zinc metal atom and cysteine sulfur of CaaX, the conformations of the substrate and inhibitor and the corresponding RMSF values, critical hydrogen bonds, and several catalytically relevant distances. These results are discussed in light of recent experimental and computational evidence that provides new insights into the activity of this enzyme.
Insights
Molecular dynamics simulations reveal key mechanistic differences between protein farnesyltransferase (FTase) substrates and inhibitors. This study offers new insights into FTase activity, crucial for cancer drug development.
Area of Science:
- Biochemistry
- Computational Biology
- Enzyme Kinetics
Background:
- Protein farnesyltransferase (FTase) is a key enzyme in post-translational modification, essential for the function of proteins implicated in cancer development.
- FTase inhibitors (FTIs) are actively investigated as anti-cancer therapeutics, with several compounds in clinical trials.
- Despite therapeutic advancements, fundamental questions regarding FTase's catalytic mechanism and substrate/inhibitor interactions persist.
Purpose of the Study:
- To elucidate the molecular mechanisms underlying the activity of protein farnesyltransferase (FTase).
- To comparatively analyze the dynamic behavior of FTase substrates and inhibitors using molecular dynamics (MD) simulations.
- To provide crucial mechanistic insights into FTase function and its interactions with CaaX peptides.
Main Methods:
- Application of specifically designed molecular mechanical parameters for MD simulations.
- Simulation of 22 CaaX peptides, acting as natural substrates or inhibitors of FTase.
- Comparative analysis of enzyme-peptide interactions, solvent effects, and key molecular properties.
Main Results:
- Detailed analysis of water molecule distribution around the catalytic zinc atom and CaaX cysteine.
- Evaluation of substrate and inhibitor conformations, RMSF values, hydrogen bonds, and critical distances.
- Identification of distinct dynamic behaviors between FTase substrates and inhibitors at the molecular level.
Conclusions:
- The study provides novel mechanistic details on FTase activity through advanced computational simulations.
- Findings offer a deeper understanding of substrate and inhibitor interactions with FTase.
- Results contribute valuable insights for the rational design of more effective FTase inhibitors for cancer therapy.
